91 related articles for article (PubMed ID: 23820828)
41. Effects of D-cycloserine, a positive modulator of N-methyl-D-aspartate receptors, and ST 587, a putative alpha-1 adrenergic agonist, individually and in combination, on the non-delayed and delayed foraging behaviour of rats assessed in the radial arm maze.
Pussinen R; Sirviö J
J Psychopharmacol; 1999; 13(2):171-9. PubMed ID: 10475724
[TBL] [Abstract][Full Text] [Related]
42. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
van Berckel BN; Evenblij CN; van Loon BJ; Maas MF; van der Geld MA; Wynne HJ; van Ree JM; Kahn RS
Neuropsychopharmacology; 1999 Aug; 21(2):203-10. PubMed ID: 10432468
[TBL] [Abstract][Full Text] [Related]
43. Medial orbitofrontal cortex lesion prevents facilitatory effects of d-cycloserine during fear extinction.
Sierra RO; Nítola LP; Duran JM; Prieto DR; León LA; Cardenas FP
Behav Brain Res; 2016 Jan; 296():379-383. PubMed ID: 26306827
[TBL] [Abstract][Full Text] [Related]
44. D-Cycloserine lowers kynurenic acid formation--new mechanism of action.
Baran H; Kepplinger B
Eur Neuropsychopharmacol; 2014 Apr; 24(4):639-44. PubMed ID: 24189377
[TBL] [Abstract][Full Text] [Related]
45. D-cycloserine added to clozapine for patients with schizophrenia.
Goff DC; Tsai G; Manoach DS; Flood J; Darby DG; Coyle JT
Am J Psychiatry; 1996 Dec; 153(12):1628-30. PubMed ID: 8942463
[TBL] [Abstract][Full Text] [Related]
46. D-cycloserine prevents relational memory deficits and suppression of long-term potentiation induced by scopolamine in the hippocampus.
Portero-Tresserra M; Del Olmo N; Martí-Nicolovius M; Guillazo-Blanch G; Vale-Martínez A
Eur Neuropsychopharmacol; 2014 Nov; 24(11):1798-807. PubMed ID: 25453488
[TBL] [Abstract][Full Text] [Related]
47. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy.
Norberg MM; Krystal JH; Tolin DF
Biol Psychiatry; 2008 Jun; 63(12):1118-26. PubMed ID: 18313643
[TBL] [Abstract][Full Text] [Related]
48. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder.
Guastella AJ; Richardson R; Lovibond PF; Rapee RM; Gaston JE; Mitchell P; Dadds MR
Biol Psychiatry; 2008 Mar; 63(6):544-9. PubMed ID: 18179785
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
Storch EA; Wilhelm S; Sprich S; Henin A; Micco J; Small BJ; McGuire J; Mutch PJ; Lewin AB; Murphy TK; Geller DA
JAMA Psychiatry; 2016 Aug; 73(8):779-88. PubMed ID: 27367832
[TBL] [Abstract][Full Text] [Related]
50. Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects.
van Berckel BN; Lipsch C; Timp S; Gispen-de Wied C; Wynne H; van Ree JM; Kahn RS
Neuropsychopharmacology; 1997 May; 16(5):317-24. PubMed ID: 9109102
[TBL] [Abstract][Full Text] [Related]
51. D-cycloserine, a partial agonist at the glycine site coupled to N-methyl-D-aspartate receptors, improves visual recognition memory in rhesus monkeys.
Matsuoka N; Aigner TG
J Pharmacol Exp Ther; 1996 Aug; 278(2):891-7. PubMed ID: 8768744
[TBL] [Abstract][Full Text] [Related]
52. Pharmacological treatments of cerebellar ataxia.
Ogawa M
Cerebellum; 2004; 3(2):107-11. PubMed ID: 15233578
[TBL] [Abstract][Full Text] [Related]
53. Cognitive behavioral group therapy and phenelzine both effective in social phobia.
Thyer BA
West J Med; 1999 Oct; 171(4):240. PubMed ID: 10578676
[No Abstract] [Full Text] [Related]
54. Commentary on Bell et al., (2012): Effectiveness of computerized cognitive behaviour therapy for anxiety disorders in secondary care.
Lampe L
Aust N Z J Psychiatry; 2012 Jul; 46(7):679-81. PubMed ID: 22735638
[No Abstract] [Full Text] [Related]
55. Quality of life following cognitive behavioral treatment for social anxiety disorder: preliminary findings.
Eng W; Coles ME; Heimberg RG; Safren SA
Depress Anxiety; 2001; 13(4):192-3. PubMed ID: 11413567
[No Abstract] [Full Text] [Related]
56. [Influence of activation and blockade of NMDA receptors on extinction of passive avoidance response in mice with different levels of anxiety].
Tomilenko RA; Dubrovina NI
Ross Fiziol Zh Im I M Sechenova; 2006 Mar; 92(3):342-50. PubMed ID: 16739644
[TBL] [Abstract][Full Text] [Related]
57. Social phobia: diagnostic issues and review of cognitive behavioral treatment strategies.
Juster HR; Heimberg RG; Holt CS
Prog Behav Modif; 1996; 30():74-98. PubMed ID: 7567677
[No Abstract] [Full Text] [Related]
58. Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate-Type Glutamate Receptor Function.
Kantrowitz JT; Swerdlow NR; Dunn W; Vinogradov S
Biol Psychiatry Cogn Neurosci Neuroimaging; 2018 Jul; 3(7):581-590. PubMed ID: 29656951
[TBL] [Abstract][Full Text] [Related]
59. Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine.
Kantrowitz JT; Epstein ML; Beggel O; Rohrig S; Lehrfeld JM; Revheim N; Lehrfeld NP; Reep J; Parker E; Silipo G; Ahissar M; Javitt DC
Brain; 2016 Dec; 139(Pt 12):3281-3295. PubMed ID: 27913408
[TBL] [Abstract][Full Text] [Related]
60. D-Cycloserine facilitation of exposure therapy improves weight regain in patients with anorexia nervosa: a pilot randomized controlled trial.
Levinson CA; Rodebaugh TL; Fewell L; Kass AE; Riley EN; Stark L; McCallum K; Lenze EJ
J Clin Psychiatry; 2015 Jun; 76(6):e787-93. PubMed ID: 26132687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
